Skip to main content
Clinical Trials/NCT06225414
NCT06225414
Active, not recruiting
Not Applicable

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

University of California, Irvine10 sites in 1 country60 target enrollmentFebruary 12, 2024
ConditionsLung Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
University of California, Irvine
Enrollment
60
Locations
10
Primary Endpoint
Number of participants with order of Low-dose CT (LDCT) for lung cancer screening (LCS)
Status
Active, not recruiting
Last Updated
3 months ago

Overview

Brief Summary

The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hispanic patients known to have lower survival rates compared with non-Hispanic whites. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases this mortality rate of lung cancer by 20%. Yet many Latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test and compare the effect of a multi-level intervention on ordering LDCT within 4 months after patient enrollment to those in an Enhanced Usual Care. Our proposed intervention includes:

  • Primary care provider notifications of patients' LCS eligibility;
  • Patients' education;
  • Patients' referral to financial navigation resources;
  • Patients' reminder to discuss LCS during primary care provider (PCP) visit.
Registry
clinicaltrials.gov
Start Date
February 12, 2024
End Date
February 1, 2026
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gelareh Sadigh

Associate Professor In Residence

University of California, Irvine

Eligibility Criteria

Inclusion Criteria

  • Aged 50- 80 years of age.
  • Be able to speak English and Spanish
  • Must have a Primary Care Provider.
  • History of 20-pack year smoking history ( based on survey self-report)
  • Current smoker or a former smoker who has quit smoking within the last 15 years (based on survey self-report)
  • Resident of California

Exclusion Criteria

  • Prior history of lung cancer
  • Chest CT for any reason in the last 12 months based on self-report and UCI EMR
  • History of Alzheimer's disease or dementia

Outcomes

Primary Outcomes

Number of participants with order of Low-dose CT (LDCT) for lung cancer screening (LCS)

Time Frame: Within 4 months of randomization

Secondary Outcomes

  • Patients' perceived severity of lung cancer(Baseline and 4 months after randomization)
  • Patients' self-efficacy of lung cancer screening(Baseline and 4 months after randomization)
  • Patients' knowledge about lung cancer screening(Baseline and 4 months after randomization)
  • Number of Participants with the documented discussion of lung cancer screening with their providers in the electronic medical record(Within 4 months of randomization)
  • Patients' perceived barriers of lung cancer screening(Baseline and 4 months after randomization)
  • Number of Participants who received LDCT for LCS(Within 4 months of randomization)
  • Patients' perceived risk of lung cancer(Baseline and 4 months after randomization)
  • Patients' perceived benefits of lung cancer screening(Baseline and 4 months after randomization)

Study Sites (10)

Loading locations...

Similar Trials